The screening of hepatitis B virus and hepatitis C virus infection in HIV-infected inpatients and evaluating correlated characteristics

Abstract

Abstract Background: This study surveyed the prevalence of hepatitis B surface antigen (HBsAg）and hepatitis C virus（HCV）antibody (anti-HCV) among inpatients with HIV infection and analyzed the correlated factors. Methods: We conducted a retrospective data collection of the HIV-infected inpatients in our hospital from January 2010 to December 2020. We utilized multivariate logistic regression to find the correlated factors. Results: The proportion of patients screened for HBsAg were 81.8% , which increased from 66.7% in 2010 to 85.7% in 2020. The proportion of patients with anti-HCV screening were 73.9%, which increased from 58.3% in 2010 to 86.7% in 2020. The prevalence of HBsAg-positive was 10.9%, which decreased from 15.0% in the period of 2010-2015 to 9.0% for HBsAg during 2016-2020. There were 4.1% cases with positive anti-HCV. Compared to 4.8% at the period of 2010-2015, there was a similar prevalence of 3.1% for anti-HCV during 2016-2020. Among HBsAg-positive cases, HBV DNA was screened in 70.8% cases. Among anti-HCV positive cases, HCV RNA were screened in 90% cases. The ALB <30 g/L, thrombocytopenia, AST >40 U/L were associated with HBsAg-positive. The AST >40 U/L and higher CD4+ T counts were associated with HIV/HCV coinfection. Conclusions: The routine screening for both HBV and HCV among HIV-positive inpatients has been greatly improved in the past decade. However, the screening of the complete HBV serological markers in HIV-positive inpatients, and HCV genotyping among HCVRNA-positive cases leaves much to be desired. A concerted effort should be taken for improving HBV vaccine compliance in the HIV-positive population and providing direct-acting antiviral therapies to HCVRNA-positive patients.